Trial Profile
Study of histological modifications, of pro-apoptotic effects and of modifications in apoptosis regulators observed after stopping 5-ASA treatment in patients with inactive ulcerative colitis (clinical and endoscopic remission) taking 5-ASA.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 28 Apr 2012
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 24 Sep 2009 New trial record.